| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Previous Article | Next Article ![]()
Molecular and Cellular Biology, April 2008, p. 2803-2814, Vol. 28, No. 8
0270-7306/08/$08.00+0 doi:10.1128/MCB.01786-07
Copyright © 2008, American Society for Microbiology. All Rights Reserved.
and p110β Regulate Cell Cycle Entry, Exhibiting Distinct Activation Kinetics in G1 Phase
Department of Immunology and Oncology, Centro Nacional de Biotecnología/CSIC, Campus de Cantoblanco, Madrid E-28049, Spain
Received 28 September 2007/ Returned for modification 9 November 2007/ Accepted 29 January 2008
Phosphoinositide 3-kinase (PI3K) is an early signaling molecule that regulates cell growth and cell cycle entry. PI3K is activated immediately after growth factor receptor stimulation (at the G0/G1 transition) and again in late G1. The two ubiquitous PI3K isoforms (p110
and p110β) are essential during embryonic development and are thought to control cell division. Nonetheless, it is presently unknown at which point each is activated during the cell cycle and whether or not they both control S-phase entry. We found that p110
was activated first in G0/G1, followed by a minor p110β activity peak. In late G1, p110
activation preceded that of p110β, which showed the maximum activity at this time. p110β activation required Ras activity, whereas p110
was first activated by tyrosine kinases and then further induced by active Ras. Interference with p110
and -β activity diminished the activation of downstream effectors with different kinetics, with a selective action of p110
in blocking early G1 events. We show that inhibition of either p110
or p110β reduced cell cycle entry. These results reveal that PI3K
and -β present distinct activation requirements and kinetics in G1 phase, with a selective action of PI3K
at the G0/G1 phase transition. Nevertheless, PI3K
and -β both regulate S-phase entry.
Published ahead of print on 19 February 2008.
| J. Bacteriol. | J. Virol. | Eukaryot. Cell |
|---|
| Microbiol. Mol. Biol. Rev. | Clin. Vaccine Immunol. | All ASM Journals |
|---|